Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K/A
2023 FY
Annual report (amended)
29 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 24
8-K
PepGen Announces Executive Team Promotions
11 Jun 24
8-K
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
14 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 24
8-K
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
13 Mar 24
8-K
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
6 Mar 24
8-K
Other Events
4 Mar 24
8-K
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
20 Feb 24
8-K
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
7 Feb 24
8-K
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
17 Jan 24
Registration and prospectus
S-8
Registration of securities for employees
6 Mar 24
424B5
Prospectus supplement for primary offering
7 Feb 24
424B5
Prospectus supplement for primary offering
8 Aug 23
S-3
Shelf registration
2 Jun 23
S-8
Registration of securities for employees
23 Mar 23
S-8
Registration of securities for employees
10 May 22
POS AM
Prospectus update (post-effective amendment)
10 May 22
424B4
Prospectus supplement with pricing info
9 May 22
S-1/A
IPO registration (amended)
4 May 22
8-A12B
Registration of securities on exchange
3 May 22
Other
EFFECT
Notice of effectiveness
20 Jun 23
CORRESP
Correspondence with SEC
14 Jun 23
UPLOAD
Letter from SEC
9 Jun 23
SEC STAFF
SEC staff action: Order
16 May 22
EFFECT
Notice of effectiveness
12 May 22
EFFECT
Notice of effectiveness
6 May 22
CERT
Certification of approval for exchange listing
5 May 22
CORRESP
Correspondence with SEC
4 May 22
CORRESP
Correspondence with SEC
3 May 22
CORRESP
Correspondence with SEC
3 May 22
Ownership
4
Peter Kolchinsky
21 Jun 24
4
HEIDI HENSON
21 Jun 24
4
LAURIE KEATING
21 Jun 24
4
Joshua Resnick
21 Jun 24
4
Christopher Ashton
21 Jun 24
4
Howard Mayer
21 Jun 24
4
Habib J Dable
21 Jun 24
4
Michelle L Mellion
13 Jun 24
4
Michelle L Mellion
7 Jun 24
144
Notice of proposed sale of securities
5 Jun 24